secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-281950
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen appoints Christopher Viehbacher as President and CEO effective Nov 14, 2022
--------------------------------------------------------------------------------

- Viehbacher succeeds Michel Vounatsos, who steps down as CEO and from the Board.
- Viehbacher receives $1.6M base salary, 150% target bonus, and initial equity awards totaling $28M (options + PSUs).
- He must purchase at least $2M of Biogen stock; then receive an RSU grant of $2M vesting in 3 years.
- Severance: 1.5x salary plus target bonus if terminated without cause or for good reason; 2x if change in control.
- Viehbacher co-founded Gurnet Point Capital, former global CEO of Sanofi.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000119312522281950/0001193125-22-281950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000119312522281950/d419645d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-281950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer